EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Prestige Biologics Co. Ltd. (334970) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Prestige Biologics Co. Ltd. KRW 983, price KRW 1,434, upside -31.5%, quality 23 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

PB Thin data Oct 3, 2026

Prestige Biologics Co. Ltd.

334970 · KQ

Weak valuationQuality is weak on top of the rich price.

Low debt
Mixed Growth (revenue 5y +132.4 %/yr in KRW)
Fair value 982.74 KRW · Overvalued (−31.5%)
Quality 23/100
Negative free cash flow
Trails peers (1/6)
Narrow moat 23/100
Thin data
⚠ Dilution
Watch Prestige Biologics Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

17,300 KRW 1,317 KRW Fair Value 982.74 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 1,317 KRW – 17,300 KRW · fair‑value band 733.39 KRW – 1,467 KRW · the 1,434 KRW price screens above the 982.74 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow Prestige Biologics Co. in your weekly email

Every Wednesday you see whether Prestige Biologics Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars.

Show more

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd. was formerly known as PrestigeBio Pharmaceuticals and changed its name to Prestige Biologics Co., Ltd. in October 2019. The company was founded in 2015 and is based in Cheongju-si, South Korea.

Stock analysis

Prestige Biologics Co. Ltd. (334970) currently trades at 1,434 KRW, while our model-based Fair Value estimate is 982.74 KRW, 31.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: 733.39 KRW (bear) to 1,467 KRW (bull), the price of 1,434 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Prestige Biologics Co. Ltd. reported revenue of 12.5B KRW in FY2024 versus 0 KRW in FY2020. Reported net income was −27.5B KRW in FY2024.

Key figures

Market cap 111B KRW (≈ $83.1M) · P/S ratio 48.8 · Return on equity −3,132% · Return on assets (EBIT) −19.3% · Operating margin −1,247% · Revenue growth (YoY) −94.5% · Free cash flow −24.0B KRW · Net debt 89.9B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 62% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −40% fair-value upside, at −31%, 334970 screens cheaper than that median.

Fair Value models

Bear 733.39 KRW Fair Value 982.74 KRW Bull 1,467 KRW
Price 1,434 KRW · Upside -31.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 700.44 KRW 938.59 KRW 1,401 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 700.44 KRW 938.59 KRW 1,401 KRW 54

Open the full fair value analysis →

Notify me when 334970 reaches fair value

Put 334970 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 23/100

Of which business quality 23 · Market factors (momentum, volatility) 9

Profitability 0
Margins and returns on capital today
Quality Growth 80
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 35
Balance sheet, leverage, solvency risk
Investment 38
Disciplined investing over empire-building
Low Volatility 27
Calm price path (market factor)
Momentum 2
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 27/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+477.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+57.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+132.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,741.0% (2019) → −268.7% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

334970 screens overvalued: fair value 31% below the price. Compare with Caregen Co →

Compare Prestige Biologics Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 43 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 23 · Bottom 25%
Fair Value upside −31.5% · Below median
Profitability
Return on assets −10.7% · Bottom 25%
Growth and dividend
Revenue growth −94.5% · Bottom 25%
Balance sheet
Debt / equity 0.24× · Highest 25%

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/S (TTM) 0.03× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 23
FUTURE (revenue growth)0 · sector 55
PAST (return on equity)0 · sector 10
HEALTH (low debt)88 · sector 98
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Caregen Co 214370 40,850 KRW 5,414 KRW −87%
ST Pharm Co 237690 91,700 KRW 50,110 KRW −45%
Oscotec Inc 039200 35,650 KRW 21,262 KRW −40%
DongKook Pharmaceutical Co 086450 22,150 KRW 28,372 KRW +28%
SHUKRAPHAR SHUKRAPHAR ₹61.84 ₹8.38 −86%
Huons Global Co 084110 22,950 KRW 46,562 KRW +103%
BINEX Co 053030 6,490 KRW 1,844 KRW −72%
Kolon Life Science Inc 102940 14,800 KRW 37,129 KRW +151%
VIKRAMTH VIKRAMTH ₹405.90 ₹444.16 +9%
JW Shinyak Corporation 067290 2,990 KRW 1,326 KRW −56%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Prestige Biologics Co. Ltd. · Fair Value
982.74 KRW −31%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Prestige Biologics Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/334970

Frequently asked questions

Is Prestige Biologics Co. Ltd. (334970) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 982.74 KRW versus a price of 1,434 KRW, about −31% upside (overvalued).
What is the fair value of 334970?
Our model-based fair value for Prestige Biologics Co. Ltd. is 982.74 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 1,434 KRW.
What is the quality score of 334970?
Prestige Biologics Co. Ltd. has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prestige Biologics Co. Ltd. (334970)?
Our model-based price target is the fair value of 982.74 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 733.39 KRW, optimistic scenario 1,467 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Prestige Biologics Co. Ltd. stock forecast for 2026?
Our models put fair value at 982.74 KRW, about −31% upside versus a price of 1,434 KRW (overvalued). Cautious scenario 733.39 KRW, optimistic scenario 1,467 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Prestige Biologics Co. Ltd. (334970)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prestige Biologics Co. Ltd. it is 982.74 KRW per share (as of Oct 3, 2026), against a price of 1,434 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Prestige Biologics Co. Ltd. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 334970 trades above its calculated fair value: price 1,434 KRW, fair value 982.74 KRW, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 334970?
No. The price is what the market pays today (1,434 KRW); the fair value is what the company's own numbers justify (982.74 KRW). For Prestige Biologics Co. Ltd. the two are 451.26 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Prestige Biologics Co. Ltd. worth?
The market values Prestige Biologics Co. Ltd. at about 111B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 1,434 KRW; our models calculate a fair value of 982.74 KRW per share.
What do the bullish and bearish scenarios say about 334970?
Our models span a range for Prestige Biologics Co. Ltd.: cautious scenario 733.39 KRW, base 982.74 KRW, optimistic 1,467 KRW per share (as of Oct 3, 2026, price 1,434 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Prestige Biologics Co. Ltd. (334970)?
Balance-sheet figures for Prestige Biologics Co. Ltd. (as of Oct 3, 2026): debt of 0.24 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is 334970 from its 52-week high?
Prestige Biologics Co. Ltd. trades at 1,434 KRW, about 62% below its 52-week high of 3,770 KRW and 9% above the low of 1,317 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 982.74 KRW is for.
Which stocks are comparable to Prestige Biologics Co. Ltd.?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prestige Biologics Co. Ltd. stock attractive at the current price?
The data as of Oct 3, 2026: price 1,434 KRW, calculated fair value 982.74 KRW (−31%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 334970 calculated?
We run Prestige Biologics Co. Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 982.74 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Prestige Biologics Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prestige Biologics Co. Ltd. (334970)?
The closing price on Oct 2, 2026 was 1,434 KRW. Our model-based fair value is 982.74 KRW, about −31% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prestige Biologics Co. Ltd. right now?
Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (733.39 KRW to 1,467 KRW) leaves room in how you read the outcome.

Key figures of Prestige Biologics Co. Ltd.

How large is the market capitalisation of Prestige Biologics Co. Ltd. (334970)?
The market capitalisation of Prestige Biologics Co. Ltd. is 111B KRW (≈ $83.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Prestige Biologics Co. Ltd. (334970)?
The price-to-sales ratio of Prestige Biologics Co. Ltd. is 48.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Prestige Biologics Co. Ltd. (334970)?
The return on equity (ROE) of Prestige Biologics Co. Ltd. is −3,132% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prestige Biologics Co. Ltd. (334970)?
On an EBIT basis the return on assets of Prestige Biologics Co. Ltd. is −19.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prestige Biologics Co. Ltd. (334970)?
The operating margin of Prestige Biologics Co. Ltd. is −1,247% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prestige Biologics Co. Ltd. (334970)?
Revenue at Prestige Biologics Co. Ltd. is growing −94.5% versus a year earlier (3y avg +57.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Prestige Biologics Co. Ltd. (334970) generate?
The free cash flow of Prestige Biologics Co. Ltd. is −24.0B KRW (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Prestige Biologics Co. Ltd. (334970) carry?
The net debt of Prestige Biologics Co. Ltd. is 89.9B KRW (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Prestige Biologics Co. Ltd. in the live analysis

One click puts Prestige Biologics Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.